- Headquarters: Vancouver, WA
- Founded: 2002
CytoDyn: FDA confirmed the number and type of evaluable patients required for submission of a Biologics License Application for PRO 140 as a combination therapy
As a result, the Company expects to complete enrollment within the near future. The FDA also confirmed that 300 patients will be required for the safety analysis in a BLA, which can be provided by all of the Company's HIV trials, providing that those patients have been on a PRO 140 therapy for 24 weeks.